YANKCOM Partnership Makes New Investment in Charles River Laboratories International, Inc. (NYSE:CRL)

YANKCOM Partnership bought a new position in Charles River Laboratories International, Inc. (NYSE:CRL) in the 4th quarter, HoldingsChannel.com reports. The fund bought 501 shares of the medical research company’s stock, valued at approximately $92,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Versant Capital Management Inc boosted its stake in shares of Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 150 shares during the period. Wolff Wiese Magana LLC purchased a new stake in shares of Charles River Laboratories International during the third quarter valued at approximately $32,000. Pinnacle Bancorp Inc. boosted its stake in shares of Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares during the period. Assetmark Inc. boosted its stake in shares of Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 173 shares during the period. Finally, ORG Wealth Partners LLC purchased a new stake in shares of Charles River Laboratories International during the fourth quarter valued at approximately $56,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

CRL has been the subject of a number of analyst reports. TD Cowen increased their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research note on Monday, November 11th. StockNews.com downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. decreased their target price on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a report on Monday. The Goldman Sachs Group decreased their target price on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. Finally, CLSA downgraded Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price for the company. in a report on Monday, November 18th. Three investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, Charles River Laboratories International currently has a consensus rating of “Hold” and an average target price of $200.79.

Charles River Laboratories International Trading Up 0.3 %

NYSE CRL opened at $166.32 on Friday. Charles River Laboratories International, Inc. has a 12 month low of $159.65 and a 12 month high of $275.00. The stock has a market cap of $8.51 billion, a P/E ratio of 20.82, a P/E/G ratio of 6.25 and a beta of 1.37. The stock’s fifty day moving average price is $181.32 and its 200-day moving average price is $194.07. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $975.99 million. During the same period in the prior year, the firm posted $2.72 earnings per share. The company’s quarterly revenue was down 1.6% on a year-over-year basis. As a group, equities analysts forecast that Charles River Laboratories International, Inc. will post 10.17 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).